SPL7013: A broad spectrum antiviral with massive future earning potential, page-9

Interesting to note from recent updates

SPL7013 NASAL SPRAY

The Company continues *commercial discussions and preparations across a range of distribution channels and customer groups (e.g. B2B, online platforms), with the product expected to be ready for market in 1H CY2021.

*commercial discussions
What does that mean – are we talking about a licensee agreement




DEP® Irinotecan timeline for dosing of patients recently

30^th September
22 patients already enrolled

20^th October
DEP® irinotecan phase 2 trial is recruiting patients rapidly, with 26 patients already dosed and a high level of interest in the study

30^th October
DEP® irinotecan phase 2 trial is rapidly recruiting patients, with 27 patients already dosed and a high level of interest in the study
The recruitment of patients in these trials is very impressive…..don’t you think
Interesting to note an expansion of DEP® Irinotecan into combination studies are about to commence

DEP® remdesivir
Following the announcement of the successful and rapid development of DEP® remdesivir, Starpharma has received an increase in the number of enquiries about the DEP® platform from pharmaceutical companies.


Delay in license agreements is not only due to covid-19 limitations

It is important to understand all these trials are expanding into combination studies, bringing substantially higher commercialisation outcomes for us shareholders. Those that are disappointed in delays……shouldn’t be……as we will definitely be better off in the long time. Our banks are going to ask us for loans (not the other way round)

With Starpharma’s healthy bank we are indeed well positioned better than at any time in the past. L